Uh-oh, it looks like your Internet Explorer is out of date.
For a better shopping experience, please upgrade now.
Widely regarded as the most innovative, successful biotech firm ever, Amgen led its industry in revenue and sales growth in 2007. Top magazines including Fortune and Industry Week have repeatedly named it one of America's best companies to work for.
In Science Lessons , Gordon BinderCEO and chairman during 1988-2000describes Amgen's climb to success. Revealing the highs and lows it experienced in the race to develop blockbuster drugs, he takes readers from the time Amgen had just three months of capital in the bank and no viable products in the pipeline to its spectacular success. The turning point? The 1989 launch of Epogen, which dramatically helped kidney dialysis patients suffering from debilitating anemia. Other landmark drugs, including Neupogen, would follow.
Through engaging anecdotes and cogent insights, Binder weaves a fascinating tale while offering his unique brand of practical management advice. Using the principals of the scientific method, he shares his recommendations for tackling pressing business challengessuch as managing creative employees, navigating the IPO process, and protecting intellectual property.
This colorful first-person account showcases the visionary science and daring business strategy that made Amgen greatoffering valuable lessons for all companies.
|Publisher:||Harvard Business Review Press|
|Product dimensions:||5.90(w) x 8.50(h) x (d)|
About the Author
Gordon Binder is the managing director of Coastview Capital LLC, a venture-capital firm he founded in 2001. From 1982 through 2000, he served as Chief Financial Officer, then Chief Executive Officer, and finally Chairman of Amgen. Forbes magazine counted him among "biotech's most respected business minds." Philip Bashe has authored or co-authored books on a wide variety of genres, including health, sports, biography, and popular culture.
Table of ContentsIntroduction 1
The Start of a Start-Up 17
Amgen Goes Public 39
The Business of Science Meets the Science of Business 57
From IPO to EPO in Four Months 75
EPO on Trial 89
Partnerships Made in Heaven-and That Other Place 107
Red Hot Summer 139
Nuclear Winter 153
How Amgen Built a Winning Team 177
How Amgen Kept Employees Committed 195
The Value of Ethics in Business 249
My Failed Retirement 269
About the Authors 293